Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
IPO Year: 1991
Exchange: NASDAQ
Website: regeneron.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/30/2025 | $662.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 5/30/2025 | $580.00 | Overweight → Equal Weight | Wells Fargo |
| 5/14/2025 | $700.00 | Neutral → Buy | Citigroup |
| 4/22/2025 | $695.00 | Overweight | Cantor Fitzgerald |
| 2/5/2025 | $762.00 → $834.00 | Market Perform → Outperform | Leerink Partners |
| 1/16/2025 | $1130.00 → $738.00 | Buy → Neutral | UBS |
| 12/10/2024 | $565.00 | Underperform | BofA Securities |
| 11/15/2024 | $1150.00 | Outperform | Wolfe Research |
| 11/14/2024 | $895.00 | Neutral | Citigroup |
| 9/24/2024 | $1175.00 → $1077.00 | Outperform → Market Perform | Leerink Partners |
RBC Capital Mkts downgraded Regeneron Pharma from Outperform to Sector Perform and set a new price target of $662.00
Wells Fargo downgraded Regeneron Pharma from Overweight to Equal Weight and set a new price target of $580.00
Citigroup upgraded Regeneron Pharma from Neutral to Buy and set a new price target of $700.00
Cantor Fitzgerald resumed coverage of Regeneron Pharma with a rating of Overweight and set a new price target of $695.00
Leerink Partners upgraded Regeneron Pharma from Market Perform to Outperform and set a new price target of $834.00 from $762.00 previously
UBS downgraded Regeneron Pharma from Buy to Neutral and set a new price target of $738.00 from $1,130.00 previously
BofA Securities resumed coverage of Regeneron Pharma with a rating of Underperform and set a new price target of $565.00
Wolfe Research initiated coverage of Regeneron Pharma with a rating of Outperform and set a new price target of $1,150.00
Citigroup initiated coverage of Regeneron Pharma with a rating of Neutral and set a new price target of $895.00
Leerink Partners downgraded Regeneron Pharma from Outperform to Market Perform and set a new price target of $1,077.00 from $1,175.00 previously
8-K - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
SCHEDULE 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)
13F-HR - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
10-Q - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
8-K - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
DEF 14A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
DEFA14A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
SCHEDULE 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)
PRE 14A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
SCHEDULE 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)